AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35357314 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable source without protective message
Number of subjects: 307
Study 35357314 — intervention group
Group type: EXPERIMENTAL
Intervention: No identified source with protective message
Number of subjects: 307
Study 35357314 — intervention group
Group type: EXPERIMENTAL
Intervention: No identified source without protective message
Number of subjects: 307
Study 35357314 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective message
Number of subjects: 307
Study 35357314 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of source and protective message interaction
Number of subjects: 307
Study 36264097 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (1200 mg daily, intravenously for two weeks, followed by oral administration for 10 weeks)
Number of subjects: 366
Study 36264097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 33038289 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 15 mg (fed state)
Number of subjects: 32
Study 33038289 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 7.5, 15, and 22.5 mg (repeated dosing)
Number of subjects: 32
Study 33038289 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 6, 12, 18, and 24 mg (with standard meal)
Number of subjects: 32
Study 33038289 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 18 mg (with high-fat meal)
Number of subjects: 32
Study 33038289 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (any dose)
Number of subjects: 32
Study 33038289 — intervention group
Group type: COMPARATOR
Intervention: Tetrabenazine 25 mg (fasted state)
Number of subjects: 32
Study 34338086 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online cognitive training intervention for threat interpretations
Number of subjects: 98
Study 34338086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study 33887492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant (2 ml per 100 cm2 surface area)
Number of subjects: 32
Study 33887492 — intervention group
Group type: COMPARATOR
Intervention: Control group (only drain placement)
Number of subjects: 32
Study 35645781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport stacking intervention (30 min, 5 days/week for 12 weeks)
Number of subjects: 48
Study 35645781 — intervention group
Group type: COMPARATOR
Intervention: Active control group (not specified)
Number of subjects: 48
Study 33189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IGFBP7
Number of subjects: 300
Study 33189655 — intervention group
Group type: EXPERIMENTAL
Intervention: GSMR analysis of IGFBP7
Number of subjects: 300
Study 33189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal mediation analysis of IGFBP7
Number of subjects: 300
Study 35523943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg t.i.d.)
Number of subjects: 90
Study 35523943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35523943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 90
Study 33148308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue intervention strategy (RIS) with budesonide/formoterol plus original treatment until AQI < 200
Number of subjects: 72
Study 33148308 — intervention group
Group type: COMPARATOR
Intervention: Original treatment (no inhaled medicine, SABA on demand, or budesonide/formoterol 160 μg/4.5 μg/dose, 1–2 dose/time, b.i.d.)
Number of subjects: 72
Study 33148308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue intervention strategy (RIS)
Number of subjects: 72
Study 36098814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg) administered 1 hour before surgery
Number of subjects: 62
Study 36098814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 33963974 — intervention group
Group type: EXPERIMENTAL
Intervention: LOAGB‐OSPAN
Number of subjects: 60
Study 33963974 — intervention group
Group type: EXPERIMENTAL
Intervention: LMGB‐OAGB
Number of subjects: 60
Study 33963974 — intervention group
Group type: COMPARATOR
Intervention: HDER
Number of subjects: 60
Study 35045567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN) 70 mg weekly for 52 weeks
Number of subjects: 59
Study 35045567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 34029455 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (250 mg every 4 weeks)
Number of subjects: 106
Study 34029455 — intervention group
Group type: COMPARATOR
Intervention: Control group (no testosterone treatment)
Number of subjects: 106
Study 34206642 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT meal (Ketonformula®)
Number of subjects: 20
Study 34206642 — intervention group
Group type: COMPARATOR
Intervention: Placebo meal
Number of subjects: 20
Study 33171566 — intervention group
Group type: COMPARATOR
Intervention: Free hand group
Number of subjects: 18
Study 33171566 — intervention group
Group type: COMPARATOR
Intervention: 1 mm group
Number of subjects: 18
Study 33171566 — intervention group
Group type: COMPARATOR
Intervention: 2 mm group
Number of subjects: 18
Study 33171566 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mm group
Number of subjects: 18
Study 33171566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm group
Number of subjects: 18
Study 33171566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm group
Number of subjects: 18
Study 33722805 — intervention group
Group type: COMPARATOR
Intervention: 18 mm balloon dilatation (Group DIL)
Number of subjects: 13
Study 33722805 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mm diameter, partially covered Hanarostent NCN (Group STENT)
Number of subjects: 13
Study 32946885 — intervention group
Group type: EXPERIMENTAL
Intervention: eMULTIPAP course
Number of subjects: 0
Study 33749823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve maternal reminiscing
Number of subjects: 242
Study 32271183 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC IBU/APAP 250/500 mg
Number of subjects: 691
Study 32271183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 32271183 — intervention group
Group type: COMPARATOR
Intervention: IBU 250 mg
Number of subjects: 691
Study 32271183 — intervention group
Group type: COMPARATOR
Intervention: APAP 650 mg
Number of subjects: 691
Study 35965962 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion combined with crystalloid coload
Number of subjects: 200
Study 35965962 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion combined with colloid coload
Number of subjects: 200
Study 32858429 — intervention group
Group type: EXPERIMENTAL
Intervention: Body armor
Number of subjects: 12
Study 32858429 — intervention group
Group type: COMPARATOR
Intervention: No body armor
Number of subjects: 12
Study 36367633 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-PIES (social cognitive theory-based pre-implementation enhancement strategy)
Number of subjects: 43
Study 36367633 — intervention group
Group type: COMPARATOR
Intervention: Active control (administrative meeting)
Number of subjects: 43
Study 33482135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule (NMT)
Number of subjects: 120
Study 33482135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32157418 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelofibrosis
Number of subjects: 2750
Study 32157418 — intervention group
Group type: COMPARATOR
Intervention: Control (without myelofibrosis)
Number of subjects: 2750
Study 32157418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib treatment
Number of subjects: 2750
Study 36403273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term nursing intervention
Number of subjects: 60
Study 36403273 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 60
Study 33713057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen at 10mg/kg/dose 8 hourly
Number of subjects: 104
Study 33713057 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diclofenac sodium at 1mg/kg/dose 8 hourly
Number of subjects: 104
Study 33713057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 104
Study 33713057 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diclofenac sodium
Number of subjects: 104
Study 34973966 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEA (intelligent detection endoscopic assistant)
Number of subjects: 17787
Study 32683359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 349
Study 32683359 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotics (penicillin or ampicillin)
Number of subjects: 349
Study 35855841 — intervention group
Group type: EXPERIMENTAL
Intervention: TWG tablets + acitretin capsules (Group A)
Number of subjects: 36
Study 35855841 — intervention group
Group type: COMPARATOR
Intervention: Compound glycyrrhizin capsules + acitretin capsules (Group B)
Number of subjects: 36
Study 35855841 — intervention group
Group type: COMPARATOR
Intervention: Acitretin capsules (Group C)
Number of subjects: 36
Study 35279215 — intervention group
Group type: EXPERIMENTAL
Intervention: AMETHIST intervention (Adapted Microplanning to Eliminate Transmission of HIV in Sex Transactions) plus the Sisters programme (usual care)
Number of subjects: 4400
Study 35279215 — intervention group
Group type: COMPARATOR
Intervention: Sisters programme (usual care)
Number of subjects: 4400
Study 33846219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 20
Study 33846219 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 36470077 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01C 20 μg
Number of subjects: 234
Study 36470077 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01C 40 μg
Number of subjects: 234
Study 36470077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 33635568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk alcohol drinking
Number of subjects: 8403
Study 33635568 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest blood cadmium quartile
Number of subjects: 8403
Study 33635568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk drinking and blood cadmium levels
Number of subjects: 8403
Study 32199723 — intervention group
Group type: COMPARATOR
Intervention: Control group (bundled recommendation video)
Number of subjects: 762
Study 32199723 — intervention group
Group type: EXPERIMENTAL
Intervention: Top concern group (control + video addressing the top HPV vaccine concern)
Number of subjects: 762
Study 32199723 — intervention group
Group type: EXPERIMENTAL
Intervention: All-concerns group (control + ≥1 videos addressing all concerns)
Number of subjects: 762
Study 35500460 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with concurrent chemoradiotherapy (CCRT) including etoposide and cisplatin, 4 cycles every 3 weeks, followed by durvalumab consolidation therapy every 4 weeks for up to 2 years.
Number of subjects: 51
Study 35500460 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with CCRT
Number of subjects: 51
Study 35500460 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51
Study 33395189 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization test of robustness applied to neural modules of the pharynx
Number of subjects: 0
Study 33395189 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-neuron loss
Number of subjects: 0
Study 35564343 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion focus
Number of subjects: 0
Study 35564343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention focus
Number of subjects: 0
Study 35564343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-oriented message framing
Number of subjects: 0
Study 35564343 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance-oriented message framing
Number of subjects: 0
Study 33819615 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS withdrawal group (IWG)
Number of subjects: 0
Study 33819615 — intervention group
Group type: COMPARATOR
Intervention: Continuous ICS group (CIG)
Number of subjects: 0
Study 34744048 — intervention group
Group type: EXPERIMENTAL
Intervention: CuN-DBS
Number of subjects: 6
Study 34744048 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN-DBS
Number of subjects: 6
Study 34744048 — intervention group
Group type: COMPARATOR
Intervention: sham-DBS
Number of subjects: 6
Study 34519140 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 101
Study 34519140 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face learning
Number of subjects: 101
Study 34519140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training methods
Number of subjects: 101
Study 36123245 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 105
Study 36123245 — intervention group
Group type: COMPARATOR
Intervention: Resection
Number of subjects: 105
Study 33592841 — intervention group
Group type: EXPERIMENTAL
Intervention: T-MSAT + integrative Korean medicine therapy (IKMT)
Number of subjects: 100
Study 33592841 — intervention group
Group type: COMPARATOR
Intervention: IKMT (Control)
Number of subjects: 100
Study 35440429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner-pharmacist telehealth collaboration
Number of subjects: 30
Study 32343940 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed reposition pharyngoplasty (BRP)
Number of subjects: 122
Study 32343940 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 122
Study 32343940 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP) with hyoid suspension (HS)
Number of subjects: 122
Study 32343940 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed reposition pharyngoplasty (BRP) with hyoid suspension (HS)
Number of subjects: 122
Study 33347474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine (RV) and pneumococcal conjugate vaccine (PCV)
Number of subjects: 2635
Study 34982486 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day of EPA/DHA
Number of subjects: 881
Study 34982486 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 881
Study 33581283 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS treatment at the dorsolateral prefrontal cortex (DLPFC) for 30 sessions over six weeks (five days per week) with a three-month follow-up.
Number of subjects: 75
Study 33581283 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment group for 30 sessions over six weeks (five days per week) with a three-month follow-up.
Number of subjects: 75
Study 34323584 — intervention group
Group type: EXPERIMENTAL
Intervention: Model implied instrumental variable, two stage least squares (MIIV‐2SLS)
Number of subjects: 0
Study 34323584 — intervention group
Group type: COMPARATOR
Intervention: Maximum likelihood (ML)
Number of subjects: 0
Study 34323584 — intervention group
Group type: COMPARATOR
Intervention: Diagonally weighted least squares (DWLS)
Number of subjects: 0
Study 34127018 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar eversion
Number of subjects: 0
Study 34127018 — intervention group
Group type: COMPARATOR
Intervention: Patellar lateral retraction
Number of subjects: 0
Study 35199592 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive cream
Number of subjects: 103
Study 35199592 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 103
Study 34306069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 60
Study 34306069 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 60
Study 35301133 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (two common dosages)
Number of subjects: 0
Study 35301133 — intervention group
Group type: EXPERIMENTAL
Intervention: Data monitoring committee (DMC) oversight
Number of subjects: 0
Study 35373017 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg Dulaglutide (DU) weekly
Number of subjects: 0
Study 35373017 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (IG) daily
Number of subjects: 0
Study 35627554 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 60
Study 35627554 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR group
Number of subjects: 60
Study 35627554 — intervention group
Group type: EXPERIMENTAL
Intervention: OCULUS group
Number of subjects: 60
Study 35627554 — intervention group
Group type: COMPARATOR
Intervention: Classic programme group (OTAGO)
Number of subjects: 60
Study 34682669 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Group (CEG)
Number of subjects: 36
Study 34682669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Group (REG)
Number of subjects: 36
Study 34682669 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy Group (PTG)
Number of subjects: 36
Study 32901323 — intervention group
Group type: EXPERIMENTAL
Intervention: Damage Control Surgery (DCS)
Number of subjects: 21
Study 32901323 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment (Group C)
Number of subjects: 21
Study 34519843 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence dish
Number of subjects: 100
Study 32503611 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Infant-Psychotherapy (PIP)
Number of subjects: 180
Study 32503611 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 180
Study 32907591 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body mass)
Number of subjects: 13
Study 32907591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 34748376 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Sigmoidoscopy (FS) screening
Number of subjects: 34272
Study 34748376 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 34272
Study 34879448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof 1% cream once daily for 12 weeks
Number of subjects: 1025
Study 34879448 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream once daily for 12 weeks
Number of subjects: 1025
Study 34382279 — intervention group
Group type: EXPERIMENTAL
Intervention: Handover education programme based on situated learning theory (lectures, expert observations, role playing, peer learning, reflection)
Number of subjects: 77
Study 34382279 — intervention group
Group type: COMPARATOR
Intervention: Lectures and observation of handovers (control group)
Number of subjects: 77
Study 34531221 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch (ES) intervention
Number of subjects: 27
Study 34531221 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no ES)
Number of subjects: 27
Study 35756424 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic hepatectomy
Number of subjects: 122
Study 36175551 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressor-exposed groups (psychosocial challenge)
Number of subjects: 76
Study 36175551 — intervention group
Group type: COMPARATOR
Intervention: Non-stressor groups (no psychosocial challenge)
Number of subjects: 76
Study 33880548 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP)
Number of subjects: 321
Study 33880548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 35582993 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=61)
Number of subjects: 121
Study 35582993 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=60)
Number of subjects: 121
Study 35582993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 34120852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DGT) with pancreatic plastic stent placement
Number of subjects: 0
Study 34120852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DGT)
Number of subjects: 0
Study 34120852 — intervention group
Group type: COMPARATOR
Intervention: Classic ERCP (Control group)
Number of subjects: 0
Study 34120852 — intervention group
Group type: EXPERIMENTAL
Intervention: Precut technique alone
Number of subjects: 0
Study 32932346 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher positive end-expiratory pressure (PEEP) approach
Number of subjects: 8
Study 35609351 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-antagonist protocol
Number of subjects: 940
Study 35609351 — intervention group
Group type: COMPARATOR
Intervention: GnRH-agonist protocol
Number of subjects: 940
Study 35609351 — intervention group
Group type: EXPERIMENTAL
Intervention: PF on the day of OPU
Number of subjects: 940
Study 33888576 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (AD)
Number of subjects: 128
Study 33888576 — intervention group
Group type: COMPARATOR
Intervention: General recommendations (GR)
Number of subjects: 128
Study 33888576 — intervention group
Group type: COMPARATOR
Intervention: Inactive device (ID)
Number of subjects: 128
Study 35357350 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine drug treatment
Number of subjects: 68
Study 35357350 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anti-infective treatment
Number of subjects: 68
Study 35357350 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 68
Study 33524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg once daily
Number of subjects: 167
Study 33524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 167
Study 33524970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 32016387 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHQ (irinotecan, 5-fluorouracil, leucovorin with high quality CT)
Number of subjects: 667
Study 32016387 — intervention group
Group type: EXPERIMENTAL
Intervention: FCSD (irinotecan, 5-fluorouracil, leucovorin with standard quality CT)
Number of subjects: 667
Study 32016387 — intervention group
Group type: EXPERIMENTAL
Intervention: FHQ (irinotecan, 5-fluorouracil, leucovorin with high quality CT)
Number of subjects: 667